ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)

Core Viewpoint - ARS Pharmaceuticals has launched a new program called "Get neffy on Us" to facilitate access to its needle-free epinephrine product, neffy, for patients with severe allergies, aiming to reduce barriers to treatment and improve convenience for patients [1][2][3] Company Overview - ARS Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on empowering at-risk patients and their caregivers to manage allergic reactions that could lead to anaphylaxis [15] - The company is commercializing neffy, an epinephrine nasal spray indicated for emergency treatment of Type I allergic reactions, including anaphylaxis, in patients aged 4 years and older who weigh at least 33 lbs [15] Program Details - The "Get neffy on Us" program offers eligible patients a free virtual visit with a healthcare provider to obtain a prescription for neffy, with a potential $0 co-pay for those with commercial insurance [1][8] - The program aims to eliminate the need for in-person office visits, making it easier for patients to access necessary medication [1][2] - The virtual consultation takes only five to ten minutes, saving time for patients and caregivers [8] Market Context - Approximately 40 million people in the U.S. live with severe allergies, but there is a limited number of allergists available to provide care [2] - Consumer surveys indicate that over 70% of Type 1 allergy patients are open to using virtual prescribing options, highlighting a demand for more accessible healthcare solutions [2] Previous Initiatives - Earlier in the year, ARS Pharmaceuticals launched the neffyInSchools program, providing eligible K-12 schools in the U.S. with neffy packs for treating severe allergic reactions, which has been distributed to over 6,600 schools across more than 20 states [3]